Assessment of eotaxin 1 in exhaled breath condensate of chronic obstructive pulmonary disease patients  by Elassal, Gehan & Mamdouh, Rasha
Egyptian Journal of Chest Diseases and Tuberculosis (2014) 63, 67–71The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLEAssessment of eotaxin 1 in exhaled breath condensate
of chronic obstructive pulmonary disease patientsGehan Elassal a,*, Rasha Mamdouh ba Chest Department, Ain Shams University, Egypt
b Clinical Pathology Department, Ain Shams University, EgyptReceived 20 October 2013; accepted 7 November 2013
Available online 5 December 2013A
ex
fo
C
*
E-
Pe
D
04
OpKEYWORDS
COPD;
Eotaxin 1;
Exhaled breath condensate;
Eosinophil chemoattractantbbreviations: COPD, chronic
haled breath condensate; IL
rced vital capacity; FEV1, fo
CR3, c chemokine receptor 3
Corresponding author.
mail address: gelassal2006@
er review under responsibil
iseases and Tuberculosis.
Production an
22-7638 ª 2014 Production
en access under CC BY-NC-ND liobstruct
, interleu
rced expi
yahoo.ie
ity of Th
d hostin
and hosti
httpcense.Abstract The aim of this work was to assess eotaxin 1 level in exhaled breath condensate of exac-
erbated and stable COPD patients in relation to normal subjects.
Subjects and methods: There were 16 COPD patients (during infective exacerbation), 16 stable
COPD patients and 20 healthy volunteers as controls matched with them in age, sex and smoking
history. EBC was collected and concentration of eotaxin 1 was measured by using Human Eotaxin
1 ELISA Kits.
Results: The mean eotaxin 1 concentration in exhaled breath condensate of studied groups was
962.5 ± 150 pg/ml in the exacerbated COPD group, 427.8 ± 186.6 pg/ml in the stable group and
89.2 ± 47.5 pg/ml in the control group. Age, smoking, FVC, FEV1, and FEV1/FVC, showed no
signiﬁcant correlation with eotaxin 1 levels among all the studied groups.
Conclusion: Eotaxin 1 levels in exhaled breath condensate of COPD patients during infective
exacerbation was signiﬁcantly higher than in stable COPD patients and both groups showed signif-
icant higher levels than the control group.
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://dx.doi.org/10.1016/j.ejcdt.2013.1The prognosis for chronic obstructive pulmonary disease
(COPD) is adversely affected by acute exacerbation, which
increases mortality and morbidity and causes an irreversible
decline of pulmonary functions [1]. It has been suggested that
patients with more frequent exacerbations have an increase in
airway inﬂammation and a higher baseline sputum interleukin
(IL)-6 and IL 8 levels, and these cytokines may predict the fre-
quency of future exacerbations [2]. It has also been reported
that not only neutrophils but also eosinophils and lymphocytes
may participate in the increased airway inﬂammation during
acute exacerbation [3]. However, the details of the mechanism
of increase in airway inﬂammation during exacerbation remain
obscure.he Egyptian Society of Chest Diseases and Tuberculosis.
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68 G. Elassal, R. MamdouhIt has been suggested that, among various causes of acute
exacerbation, respiratory tract infection due to virus or bacte-
ria may account for as much as, or even more than 80% of
COPD exacerbations [4]. Infection of airway epithelial cells in-
duces various cytokines and chemokines, such as eotaxin 1
which is a potent and selective chemoattractant for human
eosinophils .The human eotaxin receptor, CCR3 is expressed
on eosinophils, basophils and Th2 cells [5].
Eotaxin, in association with Th1-derived cytokine IL2 and
Th2 – derived cytokine IL4 is an important T lymphocyte acti-
vator, stimulating the directional migration, adhesion, accu-
mulation, and recruitment of T lymphocytes in parallel with
the accumulation of eosinophils and basophils during the pro-
cess of certain types of inﬂammation [6].
Exhaled breath condensate (EBC) is a promising source of
biomarkers of lung disease. It is important to note that EBC is
not a biomarker, but rather a matrix in which biomarkers may
be identiﬁed, in that way equivalent to blood, sweat, tears, ur-
ine and saliva. EBC may be thought of either as a body ﬂuid or
as a condensate of exhaled gas [7].
Eotaxin 1 was assessed by many studies in patients with
bronchial asthma. It was measured in serum and EBC of stable
and unstable asthmatics and correlated with the level of con-
trol of asthma and monitoring of inﬂammatory process [8,9].
Many studies have investigated eotaxin 1 in serum and spu-
tum of COPD patients, however, up to our knowledge no stud-
ies have investigated eotaxin 1 in exhaled breath condensate of
COPD patients.
So, the aim of this work was to assess eotaxin 1 level in ex-
haled breath condensate of exacerbated and stable COPD pa-
tients in comparison to normal subjects.
Subjects and methods
This study was conducted in the chest department and outpa-
tient clinic of the Ain Shams University hospital in the period
between February and April 2013. Fifty-two individuals were
included in the study; they were 32 COPD patients (diagnosed
according to GOLD 2011 guidelines) and 20 controls. The can-
didates were classiﬁed into: 16 COPD patients (during infective
exacerbation), 16 stable COPD patients and 20 healthy volun-
teers as controls matched with them in age, sex and smoking
history.
Exclusion criteria
The following patients were excluded from the study:
- Patients with history of bronchial asthma.
- Patients with history of intake of inhaled or oral steroids.
- Patients with heart failure.
- Patients with pulmonary thromboembolism.
All candidates were subjected to:
- Full history taking.
- Thorough clinical examination.
- Chest X-ray.
- Routine laboratory investigations.
- Pulmonary spirometry to measure: FEV1, FVC and FEV1/
FVC ratio. It was done using a Flowmate spirometer.- EBC was collected by using a commercially available con-
denser (EcoScreen; Jaeger, Wu¨rzburg, Germany) according
to the current ATS/ERS guidelines [10]. Patients were
instructed to breathe tidally for 10 min with nose clip.
The respiratory rate ranged from 15 to 20 breaths/min.
Patients were asked to swallow their saliva periodically
and to temporarily discontinue collection if they need to
cough. At the end of collection 1.5–3.5 ml aliquots of con-
densate were transferred to Eppendorf tubes and immedi-
ately frozen. Samples were stored at 20 C [11].
Concentration of eotaxin 1 was measured by using Human
Eotaxin 1 ELISA Kits.
Statistical analysis
Continuous variables are expressed as mean and standard
deviation. Categorical variables are expressed as frequencies
and percents. A signiﬁcance level of P< 0.05 was used in all
tests. All statistical procedures were carried out using SPSS
version 15 for Windows (SPSS Inc., Chicago, IL, USA).
Results
The current study was conducted on 52 male subjects, they
were divided into: 16 exacerbated COPD patients, 16 stable
COPD patients and 20 healthy volunteers as the control group.
Their mean age was (59.5 ± 11.6, 56.9 ± 12.0 and
53.2 ± 5.2) years, respectively, with no statistical signiﬁcant
difference.
Among the exacerbated group 14 patients out of 16
(87.5%) were current smokers and two patients (12.5%) were
ex-smoker with a mean smoking index 36.8 ± 16.8 pack year.
While in the stable group 10 patients out of 16 (62.5%) were
smokers, 5 (31.3%) patients were ex-smokers and one patient
out of 16 (6.3%) was a non-smoker with a mean smoking in-
dex 42.4 ± 17.6 pack-year. In the control group there were
18 out of 20 (90%) current smokers, one ex-smoker (5%)
and one non-smoker (5%). There was no statistical signiﬁcant
difference between the studied groups as regard smoking habit.
The spirometry showed no statistical signiﬁcant difference
between the exacerbated and stable COPD group as the mean
FVC was 64.5%± 21.8 and 64.2%± 20.7 of the predicted in
exacerbated and stable COPD patients, respectively. The mean
FEV1 was 48.0%± 19.8 and 47.6%± 20.9 in exacerbated
and stable groups, respectively. Also the mean FEV1/FVC ra-
tio was 58.2%± 10.6 and 58%± 9.9 in exacerbated and sta-
ble groups, respectively.
As regard eotaxin 1 concentration in exhaled breath con-
densate of studied groups it was 962.5 ± 150 pg/ml in the
exacerbated COPD group, 427.8 ± 186.6 pg/ml in the stable
group and 89.2 ± 47.5 pg/ml in the control group.
Table 1 shows no signiﬁcant difference between exacer-
bated and stable COPD cases as regard age, smoking habits,
and spirometry. However, a highly signiﬁcant difference
between exacerbated and stable COPD cases was present as
regard eotaxin 1 level with higher level among the exacerbated
group.
Table 2 shows no signiﬁcant difference between exacer-
bated and controls as regard age and smoking habits.
However, a highly signiﬁcant difference between exacerbated
Table 1 Comparison between exacerbated and stable as regard personal and medical data.
Group t/x2 P Sig
Exacerbated Stable
Mean ±SD Mean ±SD
Age years 59.5 11.6 56.9 12.0 .614 .544* NS
Smoking Smoker 14 87.5% 10 62.5% 2.800 .220** NS
Ex smoker 2 12.5% 5 31.3%
Non smoker 0 0% 1 6.3%
Smoking index pack/yr 32.8 15.6 42.4 17.6 –1.410 .173* NS
FVC 64.5 21.8 64.2 20.7 .039 .969* NS
FEV1 48.0 19.8 47.6 20.9 .058 .954* NS
FEV1FVC 58.2 10.6 58.0 9.9 .058 .954* NS
Eotaxin 1 conc. 962.5 150.0 427.8 186.6 8.934 .0001* HS
* Student t test.
** Chi square test.
Table 2 Comparison between exacerbated and control as regard personal and medical data.
Group t/x2 P Sig
Exacerbated COPD Control
Mean ±SD Mean ±SD
Age years 59.5 11.6 53.20 5.217 2.011 .058* NS
Smoking Smoker 14 87.5% 18 90.0% 1.425 .768** NS
Ex smoker 2 12.5% 1 5.0%
Non smoker 0 0% 1 5.0%
Eotaxin 1 conc. 962.5 150.0 89.2 47.5 24.6 .0001* HS
* Student t test.
** Chi square test.
Table 3 Comparison between stable and control as regard personal and medical data.
Group t/x2 P Sig
Stable COPD Control
Mean ±SD Mean ±SD
Age years 56.9 12.0 53.2 5.2 1.162 .259 NS
Smoking Smoker 10 62.5% 18 90.0% 4.56 .069 NS
Ex smoker 5 31.3% 1 5.0%
Non smoker 1 6.3% 1 5.0%
Eotaxin 1 conc. 427.8 186.6 89.2 47.5 7.83 .0001 HS
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level among the exacerbated group.
Table 3 shows no statistical signiﬁcant difference between
stable and controls as regard age and smoking habits. How-
ever, a highly signiﬁcant difference between stable and controls
was present as regard eotaxin 1 level with higher level among
the stable group. That is to say there was signiﬁcant difference
in the level of eotaxin 1 concentration in EBC of studied
groups showing the highest level in the exacerbated group
and lowest in control group (Fig. 1).
Age, smoking, FVC, FEV1, and FEV1/FVC, showed no
signiﬁcant correlation with eotaxin 1 levels among all the stud-
ied groups.
Discussion
To our knowledge, this is the ﬁrst time eotaxin 1 level was as-
sessed in exhaled breath condensate of exacerbated and stable
COPD patients.Many reports have studied eotaxin 1 level in serum, sputum
and exhaled breath condensate of stable and unstable asth-
matic patients. Other reports studied eotaxin 1 levels in serum
and sputum of COPD patients, but not in exhaled breath
condensate. So we faced lack of data regarding eotaxin 1 in
exhaled breath condensate of COPD patients to compare our
results with these data.
In the current study we aimed to assess eotaxin 1 level in
exhaled breath condensate of COPD patients during infective
exacerbation, and stable COPD patients in comparison to
the control group.
Our study documented that eotaxin 1 level in exhaled
breath condensate of COPD patients during exacerbation
was signiﬁcantly higher than that of the control group. This
coincides with Fujimoto et al. [12] who investigated many
inﬂammatory cells such as lymphocytes, neutrophils, and
eosinophils and mediators such as interleukin-8 and eotaxin
in sputum of COPD patients during acute exacerbation and
found a signiﬁcant difference in these cells and mediators
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Figure 1 A signiﬁcant difference in the level of eotaxin 1
concentration in EBC of studied groups showing the highest level
in the exacerbated group and lowest in control group.
70 G. Elassal, R. Mamdouhincluding eotaxin between COPD patients and the control
group.
In the current study the level of eotaxin 1 in EBC of stable
COPD was signiﬁcantly higher than that of the control group,
however it is still lower than the level in the exacerbated group.
This agree with Rozyk et al. [13] who studied the serum eo-
taxin and serum eosinophil cationic protein in asthmatic and
COPD patients and found that serum eotaxin is signiﬁcantly
higher in COPD patients than in asthmatic patients or the con-
trol group.
This also coincides to some extent with Fujimoto et al. [12]
who investigated eotaxin level (among other mediators and
inﬂammatory cells) in sputum of stable and acutely exacer-
bated COPD patients, and stated that the eotaxin level in spu-
tum from COPD patients in a stable phase was signiﬁcantly
higher than that from the age-matched control group. On
the other hand, they disagree with our results in that they
found no signiﬁcant difference between exacerbated and stable
COPD patients as regard eotaxin level in sputum.
In another study to investigate whether eosinophils and T
lymphocytes may be indicators of disease stability in COPD
patients, the researchers studied 45 COPD patients with mod-
erately severe airway obstruction and 11 controls. Lung lavage
and plasma samples were examined for eotaxin and other cyto-
kines. The team found that lung lavage eotaxin 1 levels were
signiﬁcantly higher in patients with rapidly progressing COPD
than in stable COPD patients and controls. They also found
that, in contrast, patients with stable COPD had signiﬁcantly
lower plasma levels of eotaxin 1 than both rapid decliners
and controls, who had the highest levels [14].
Thus, all these results including ours, suggest that eotaxin
may participate in eosinophilic inﬂammation as eosinophil
chemoattractants in COPD patients during exacerbation.
In the current study there was no statistical signiﬁcant dif-
ference between the studied groups as regard the smoking ha-
bit. This coincides with another study [15] which was done to
compare the eosinophil and neutrophil chemotactic activity
contained in EBC from healthy subjects and patients with
COPD. They stated that smoking did not inﬂuence eosinophil
chemotactic activity in healthy subjects or patients with
COPD.
On the other hand, Zhu et al. [16] who studied the gene
expression of interleukin-4, interleukin-5 eosinophil chemoat-
tractant in exacerbation of bronchitis, found that expressionof eotaxin did not show any signiﬁcant change in smokers with
chronic bronchitis than in healthy non smokers. Whereas
Fujimoto et al. [12] found that eotaxin in the supernatant of
sputum from patients with both stable and unstable COPD
groups in a stable phase was signiﬁcantly higher than those
in healthy non smokers.
However, in our study there were only two non smokers,
one of them in the stable COPD group and the other was in
the control group and all other candidates were smokers or
ex-smokers to keep matching between studied groups as regard
smoking habit. Thus it is difﬁcult for us to compare between
smokers and non smokers.
In the current study FVC, FEV1 and FEV1/FVC, showed
no signiﬁcant correlation with eotaxin 1 levels among all the
studied groups. These results agree with Fujimoto et al. [12]
who found no signiﬁcant difference between stable COPD,
unstable COPD and non smokers groups as regard pulmonary
functions in correlation with eotaxin levels.
However, these results disagree with another study [13] that
investigated eotaxin in serum of patients with asthma or
chronic obstructive pulmonary disease and reported that ser-
um eotaxin levels were inversely related to the lung function
(FEV1) in patients with asthma or COPD.
In conclusion, we found signiﬁcantly higher eotaxin 1 levels
in exhaled breath condensate of exacerbated and stable COPD
patients in comparison with the control group with much high-
er levels in the exacerbated group. These results support the re-
ports suggested that not only neutrophils but also eosinophils
and lymphocytes may participate in the increased airway
inﬂammation during acute exacerbation. Thus, the low molec-
ular weight compounds that have been developed and can
block the eotaxin receptors CCR3 and prevent stimulation
by eotaxin, may provide the potential for oral drugs that can
prevent eosinophil recruitment into the lung and the associated
damage and dysfunction. These drugs may provide a promis-
ing way to control exacerbations and/or decrease their
frequencies.
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